Physician profile
Than Win
NPI 1346341997
$2,040.89
in general payments reported to CMS, 2019-2025
15 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $66.76 · 2021: $108 · 2023: $238 · 2024: $199 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.65 | 2019-2025 | Rinvoq |
| Amgen INC. | $379.76 | 2019-2025 | |
| Janssen Biotech, INC. | $241.92 | 2019-2025 | Simponi Aria, Tremfya |
| Novartis Pharmaceuticals Corporation | $153.49 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $144.59 | 2019-2025 | Opsumit, Uptravi |
| Lilly USA, LLC | $121.85 | 2019 | |
| Sanofi-Aventis U.S. LLC | $90.99 | 2019 | |
| Pfizer INC. | $70.16 | 2019 | |
| Genentech USA, INC. | $49.13 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $43.45 | 2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $41.10 | 2019 | |
| Genzyme Corporation | $39.02 | 2019 | |
| Glaxosmithkline, LLC. | $34.65 | 2019 | |
| Ucb, INC. | $25.80 | 2019 | |
| Radius Health, INC. | $18.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Than Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.